Jinghua Yan

List of Publications by Citations

102 papers	7,543 citations	34 h-index	86 g-index
106 ext. papers	9,844 ext. citations	15.2 avg, IF	6.09 L-index

#	Paper	IF	Citations
102	Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell*, **2020**, 181, 894-904.e9	56.2	1513
101	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature*, **2020**, 584, 120-124	50.4	844
100	Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. *Nature Communications*, **2017**, 8, 15092	17.4	484
99	Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. *Nature*, **2013**, 500, 227-31	50.4	466
98	Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. *Cell Host and Microbe*, **2016**, 19, 696-704	23.4	321
97	Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice. *Cell*, **2016**, 167, 1511-1524.e10	56.2	251
96	A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell*, **2020**, 182, 722-733.e11	56.2	227
95	Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. *Cell Host and Microbe*, **2014**, 16, 328-37	23.4	198
94	Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. *Cell*, **2016**, 164, 258-268	56.2	165
93	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. *Science Translational Medicine*, **2016**, 8, 369ra179	17.5	152
92	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. *Lancet Infectious Diseases, The*, **2021**, 21, 1107-1119	25.5	145
91	The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. *Nature Structural and Molecular Biology*, **2010**, 17, 1266-8	17.6	141
90	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. *Nature Communications*, **2017**, 8, 14369	17.4	128
89	Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virus. *Nature Communications*, **2014**, 5, 3142	17.4	120
88	Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. *Journal of Virology*, **2013**, 87, 13134-40	6.6	118
87	A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. *Cell Research*, **2015**, 25, 1237-49	24.7	116
86	Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. *Journal of Biological Chemistry*, **2018**, 293, 11709-11726	5.4	114

85	Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. *Biosensors and Bioelectronics*, **2020**, 173, 112817	11.8	88
84	Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. *Protein and Cell*, **2010**, 1, 459-67	7.2	85
83	COVID-19 Vaccines: Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant (Adv. Mater. 40/2020). *Advanced Materials*, **2020**, 32, 2070303	24	78
82	Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. *Cell Research*, **2017**, 27, 151-153	24.7	72
81	MERS-CoV spike protein: Targets for vaccines and therapeutics. *Antiviral Research*, **2016**, 133, 165-77	10.8	72
80	Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. *Cell Discovery*, **2020**, 6, 68	22.3	69
79	Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion. *Nature Communications*, **2011**, 2, 577	17.4	66
78	Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004686	4.8	63
77	Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. *Antiviral Research*, **2017**, 140, 55-61	10.8	59
76	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus. *Journal of Virology*, **2016**, 90, 9114-27	6.6	56
75	Cryo-EM Structure of the African Swine Fever Virus. *Cell Host and Microbe*, **2019**, 26, 836-843.e3	23.4	56
74	Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage. *Journal of Virology*, **2018**, 92,	6.6	55
73	Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. *Oncotarget*, **2017**, 8, 67129-67139	3.3	48
72	Endogenous Cellular MicroRNAs Mediate Antiviral Defense against Influenza A Virus. *Molecular Therapy - Nucleic Acids*, **2018**, 10, 361-375	10.7	45
71	Molecular Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus Envelope Protein. *Cell*, **2019**, 177, 1714-1724.e12	56.2	36
70	Structural insight into RNA synthesis by influenza D polymerase. *Nature Microbiology*, **2019**, 4, 1750-1759	26.6	35
69	Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B. *Cell*, **2019**, 177, 1553-1565.e16	56.2	34
68	Adaptation of avian influenza A (H6N1) virus from avian to human receptor-binding preference. *EMBO Journal*, **2015**, 34, 1661-73	13	34

67	Monoclonal Antibodies against Zika Virus: Therapeutics and Their Implications for Vaccine Design. *Journal of Virology*, **2017**, 91,	6.6	33
66	Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. *Journal of Biological Chemistry*, **2011**, 286, 18013-25	5.4	33
65	Cross-species recognition of SARS-CoV-2 to bat ACE2. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	32
64	Interaction of Hsp40 with influenza virus M2 protein: implications for PKR signaling pathway. *Protein and Cell*, **2010**, 1, 944-55	7.2	31
63	Molecular basis of antibody-mediated neutralization and protection against flavivirus. *IUBMB Life*, **2016**, 68, 783-91	4.7	31
62	Crystal structure of herpes simplex virus 2 gD bound to nectin-1 reveals a conserved mode of receptor recognition. *Journal of Virology*, **2014**, 88, 13678-88	6.6	29
61	The two-component system Ihk/Irr contributes to the virulence of Streptococcus suis serotype 2 strain 05ZYH33 through alteration of the bacterial cell metabolism. *Microbiology (United Kingdom)*, **2012**, 158, 1852-1866	2.9	28
60	hNUDT16: a universal decapping enzyme for small nucleolar RNA and cytoplasmic mRNA. *Protein and Cell*, **2011**, 2, 64-73	7.2	27
59	Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. *Antiviral Research*, **2017**, 137, 125-130	10.8	26
58	Structural basis of nectin-1 recognition by pseudorabies virus glycoprotein D. *PLoS Pathogens*, **2017**, 13, e1006314	7.6	26
57	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. *Protein and Cell*, **2016**, 7, 866-877	7.2	26
56	Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. *Advanced Materials*, **2020**, 32, e2004210	24	26
55	Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope. *Cell Reports*, **2019**, 26, 438-446.e5	10.6	26
54	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. *Nature Communications*, **2021**, 12, 776	17.4	26
53	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. *Nature Communications*, **2021**, 12, 6103	17.4	24
52	COVID-19 mRNA vaccines. *Journal of Genetics and Genomics*, **2021**, 48, 107-114	4	24
51	Changes in the Length of the Neuraminidase Stalk Region Impact H7N9 Virulence in Mice. *Journal of Virology*, **2016**, 90, 2142-9	6.6	23
50	Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. *Nature Microbiology*, **2019**, 4, 1231-1241	26.6	22

49	Structural and functional analysis of an anchorless fibronectin-binding protein FBPS from Gram-positive bacterium Streptococcus suis. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 13869-13874	11.5	21
48	Swift and Strong NK Cell Responses Protect 129 Mice against High-Dose Influenza Virus Infection. *Journal of Immunology*, **2016**, 196, 1842-54	5.3	21
47	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.. *New England Journal of Medicine*, **2022**,	59.2	21
46	Bacterial effector NleL promotes enterohemorrhagic E. coli-induced attaching and effacing lesions by ubiquitylating and inactivating JNK. *PLoS Pathogens*, **2017**, 13, e1006534	7.6	20
45	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses. *Journal of Medicinal Chemistry*, **2016**, 59, 6303-12	8.3	20
44	PILR and PILR have a siglec fold and provide the basis of binding to sialic acid. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 8221-6	11.5	19
43	Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. *Cellular and Molecular Immunology*, **2020**, 17, 966-975	15.4	19
42	Genomic and transcriptomic analysis of NDM-1 Klebsiella pneumoniae in spaceflight reveal mechanisms underlying environmental adaptability. *Scientific Reports*, **2014**, 4, 6216	4.9	18
41	Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. *Journal of Infectious Diseases*, **2016**, 214, 1937-1946	7	18
40	Avian-to-Human Receptor-Binding Adaptation of Avian H7N9 Influenza Virus Hemagglutinin. *Cell Reports*, **2019**, 29, 2217-2228.e5	10.6	18
39	Structural basis of collagen recognition by human osteoclast-associated receptor and design of osteoclastogenesis inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 1038-43	11.5	17
38	Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. *MBio*, **2018**, 9,	7.8	17
37	The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. *Signal Transduction and Targeted Therapy*, **2020**, 5, 16	21	16
36	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. *IScience*, **2019**, 14, 113-124	6.1	15
35	N-glycosylation of PD-1 promotes binding of camrelizumab. *EMBO Reports*, **2020**, 21, e51444	6.5	14
34	Putative Receptor Binding Domain of Bat-Derived Coronavirus HKU9 Spike Protein: Evolution of Betacoronavirus Receptor Binding Motifs. *Biochemistry*, **2016**, 55, 5977-5988	3.2	14
33	Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. *Cell Reports*, **2018**, 25, 909-920.e4	10.6	14
32	The structural basis of African swine fever virus pA104R binding to DNA and its inhibition by stilbene derivatives. *Proceedings of the National Academy of Sciences of the United States of America* , **2020**, 117, 11000-11009	11.5	13

31	Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. *Emerging Microbes and Infections*, **2020**, 9, 1238-1241	18.9	12
30	Molecular Basis of Binding between Middle East Respiratory Syndrome Coronavirus and CD26 from Seven Bat Species. *Journal of Virology*, **2020**, 94,	6.6	12
29	The NS1 gene from bat-derived influenza-like virus H17N10 can be rescued in influenza A PR8 backbone. *Journal of General Virology*, **2016**, 97, 1797-1806	4.9	11
28	Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding. *Protein and Cell*, **2013**, 4, 761-70	7.2	10
27	N□terminal acetylation for T cell recognition: molecular basis of MHC class I-restricted n□acetylpeptide presentation. *Journal of Immunology*, **2014**, 192, 5509-19	5.3	9
26	Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. *Cell Discovery*, **2019**, 5, 21	22.3	8
25	Characterization of the nucleocytoplasmic shuttle of the matrix protein of influenza B virus. *Journal of Virology*, **2014**, 88, 7464-73	6.6	8
24	Distribution of sialic acid receptors and experimental infections with different subtypes of influenza A viruses in Qinghai-Tibet plateau wild pika. *Virology Journal*, **2015**, 12, 63	6.1	8
23	Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses. *Nature Communications*, **2020**, 11, 5964	17.4	8
22	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0035021	5.9	7
21	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. *Nature Communications*, **2021**, 12, 5000	17.4	7
20	Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells. *Cell Reports*, **2019**, 27, 1205-1220.e4	10.6	6
19	Hemagglutinin-specific CD4 T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. *Vaccine*, **2017**, 35, 5644-5652	4.1	6
18	SARS-CoV-2 virus: Vaccines in development. *Fundamental Research*, **2021**, 1, 131-138		6
17	Both structure and function of human monoclonal antibodies contribute to enhancement of Zika virus infectivity in vitro. *Science China Life Sciences*, **2017**, 60, 1396-1398	8.5	5
16	Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by Acinetobacter Baumannii: a case control study. *BMC Infectious Diseases*, **2018**, 18, 664	4	5
15	A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates.. *Emerging Microbes and Infections*, **2022**, 1-39	18.9	5
14	MicroRNAs: the novel targets for Ebola drugs. *Science China Life Sciences*, **2014**, 57, 985-6	8.5	4

13	Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. *Cell Discovery*, **2021**, 7, 91	22.3	4
12	Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection		4
11	Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity. *Scientific Reports*, **2020**, 10, 16615	4.9	4
10	Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. *Nature Immunology*, **2021**, 22, 958-968	19.1	4
9	Targeted disruption of Noc4l leads to preimplantation embryonic lethality in mice. *Protein and Cell*, **2017**, 8, 230-235	7.2	3
8	CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. *Tuberculosis*, **2017**, 107, 5-12	2.6	3
7	Molecular basis of pangolin ACE2 engaged by COVID-19 virus. *Chinese Science Bulletin*, **2021**, 66, 73-84	2.9	3
6	Macrophage deletion of Noc4l triggers endosomal TLR4/TRIF signal and leads to insulin resistance. *Nature Communications*, **2021**, 12, 6121	17.4	2
5	Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. *Signal Transduction and Targeted Therapy*, **2020**, 5, 158	21	2
4	An infectious clone of the highly pathogenic porcine reproductive and respiratory syndrome virus: Topology of glycoprotein 3 (GP3) addressing the intrachain disulfide bonds. *Science Bulletin*, **2011**, 56, 2785-2793		1
3	Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.. *Emerging Microbes and Infections*, **2022**, 1-15	18.9	1
2	A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 23	21	0
1	Isolation of Monoclonal Antibodies from Zika Virus-Infected Patient Samples. *Methods in Molecular Biology*, **2020**, 2142, 261-288	1.4	